Featured
< Back to NewsGleason IP Testimony Supports Client’s Successful Case
August 3, 2020
Gleason IP provided expert testimony on behalf of Teva Pharmaceuticals to establish that the asserted patent claims allegedly covering Adapt Pharma’s opioid overdose drug were invalid due to obviousness, and that the marketplace performance of Narcan® was attributable to features already known in the prior art, among other extrinsic factors unrelated to the Patents-in-Suit. Engagement In... Read More
Remote Depositions in Response to COVID-19
August 3, 2020
The COVID-19 pandemic and related stay-at-home directives have led to an increase in remote depositions. Historically, attorneys have been reluctant to conduct remote depositions, but there can be certain advantages to be gained from their adoption. On several occasions, Gleason Managing Directors have been deposed virtually and are providing insight for consideration to aid in... Read More
Pricing in the Pharmaceutical Industry
August 3, 2020
Drug pricing in the United States has been a political hot topic in recent years. On July 24, 2020, President Trump signed four executive orders on lowering drug prices. This multifaceted issue has numerous stakeholders with far reaching financial impacts. The backdrop of the current global pandemic creates additional complications for pharmaceutical companies seeking to... Read More
August 3, 2020
Recently the practice of establishing so called patent-thickets for biologic products has been questioned as a potentially abusive way of preventing biosimilar competition. In June 2020, the Honorable Judge Manish S. Shah in the United States District Court for the Northern District of Illinois Eastern Division issued a Memorandum Opinion and Order dismissing a class... Read More